Allurion relaunches balloon in France after ANSM clearance; exploring combo GLP-1 trial

ALLURION TECHNOLOGIES, INC.

ANSM cleared Allurion to resume sales of Allurion Balloon in France, effective immediately (Feb 13, 2025).
France historically represented approximately 15% of Allurion's revenue.
Company plans clinical trial combining balloon with GLP-1s to study prevention of muscle loss during GLP-1 therapy.
Previous study: patients with balloon gained 5.6% lean body mass while losing 14% total weight over 4 months.
Another study: 167 patients lost 15.7% weight with no change in muscle mass.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.